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Abstract  
 
Objective: This systematic review examines whether there is a relationship between objective 
measures of chemotherapy-related cognitive impairment in patients with solid cancer tumours and 
health related quality of life (HRQoL).  
 
Methods: Multiple online databases were searched (including Ovid MEDLINE, EMBASE, 
PsycINFO, PsycARTICLES, CINAHL, PubMed and Web of Science) in order to identify articles 
published between 1980 and 2016 examining the extent of chemotherapy-related cognitive deficit 
and its relationship with HRQoL in cancer patients.  Of 2769 potentially relevant articles, 17 
studies met the inclusion criteria for the current review. 
 
Results: Evidence for the presence of cognitive impairment in patients treated with chemotherapy 
was found in 15 of the 17 studies. Out of the 15 studies finding some sort of cognitive impairment, 
12 were in female breast cancer patients, 2 in bowel cancer, and 1 each in ovarian and lung 
cancer. Three of the 15 studies found a significant relationship between various objectively 
measured cognitively impaired domains and specific HRQoL outcomes. There was, however, only 
limited testing of the relationships between quantifiable cognitive dysfunction and HRQoL 
domains. 
 
Conclusions: This review suggests that in patients with solid tumours, where there is a relationship 
between chemotherapy treatment and cognitive impairment, the type and level of cognitive decline 
does not consistently appear to have an impact on such patients’ HRQoL. This could be partly 
explained by variations in study design, measures used, definitions of cognitive impairment, 
varying measurement time frames, small sample sizes and differences in disease severity and 
type of treatment regimes.  
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Background  
 
The effectiveness of chemotherapy drugs in treating a range of cancers has improved significantly 
in recent decades. Whether used alone, or in combination with other treatments, the result has 
been a marked reduction in disease recurrence and an increase in survival rates [1] doubling in 
the United Kingdom (UK) in the last 40 years [2]. This has been most notable in the treatment of 
female breast cancer and colorectal cancer (CRC), with an increase in absolute survival between 
1971/72 and 2010/11 of 38% and 35% respectively [2]. UK survival at 5 years for colon cancer 
patients diagnosed between 2005–2009 and followed up to 2010 rose to 54% for men and 55% for 
women from 26% and 25% respectively for those diagnosed between 1971-75 and followed up to 
1995. Similar increases were found in rectal cancer where 5-year survival was 55% for men and 
57% for women compared to 27% and 29% respectively over the same time periods [3]. There has 
also been an increase in the 10-year relative survival for both sexes in CRC from just over 30% 
among those followed up during 1981-1986 to over 45% among those followed up during 1997-
2001 [4]. 
 
These achievements have been attributed to screening, early detection and treatments. 
Nonetheless the pharmaceutical treatments used in these conditions do have side effects. The 
most common side effects of chemotherapy drugs are nausea, vomiting and fatigue [5]. 
Additionally, a decline in cognitive function, colloquially known as “chemofog” or “chemobrain”, has 
been reported by some patients following chemotherapy with estimates of patient numbers 
affected by this self-report of cognitive decline varying widely [6, 7]. Individuals report experiencing 
problems with concentration, memory, learning and language in their everyday life [8]. However, 
the number of patients reporting cognitive problems exceeds those with objectively measurable 
impairment, and even when present, the two do not necessarily co-occur [8, 9].  
 
Studies have demonstrated that some degree of objectively measured post-chemotherapy 
cognitive difficulty is experienced by 16%-75% of adult patients with solid tumours [5, 10]. The 
majority of studies are of breast cancer patients, with a smaller number for lung, prostate, CRC 
and ovarian cancer patients [10-19]. It is possible that the large degree of variation is due to a 
range of confounders such as patient population diversity, cancer stage and treatment regimes as 
well as methodological differences between studies, including inconsistent definitions of cognitive 
impairment and the use of different measures to assess such impairment [20-22]. Early studies 
also suffer from methodological limitations such as small sample sizes, many using cross-
sectional designs and some failing to conduct pre-treatment cognitive function evaluations [22]. 
Later studies used longitudinal designs, although sample sizes remained small and few studies 
used a comparison group. All of this has limited the conclusions that may be drawn from the data. 
 
Nevertheless, some studies have examined a range of cognitive abilities and reported memory, 
processing speed and executive function as being the most likely to be adversely affected by 
adjuvant chemotherapy treatment [15, 17, 20, 22, 23]. The degree of impairment observed is 
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usually mild to moderate [24–27]. Even so, these cognitive deficits may have implications for 
patients’ health related quality of life (HRQoL) [28] as well as their daily functioning, work 
performance and health care [29, 30].  
 
HRQoL is an independent predictor of survival and response to therapy in cancer patients [31-33]. 
With the increase in survival times HRQoL has become a meaningful outcome measure for cancer 
patients [34]. An understanding of any link between chemotherapy-related cognitive impairment 
and HRQoL domains (e.g. emotional, physical, functional, social, financial and spiritual status) will 
provide medical teams and patients’ with a broader picture of the related consequences of 
chemotherapy treatment. Such knowledge may be a helpful catalyst in the development of 
interventions, which aim to improve coping and adjustment [35]. 
This review’s primary aim is to identify and synthesise research concerned with the relationship 
between objectively measured chemotherapy-related cognitive impairment and HRQoL in adult 
patients who received chemotherapy for treatment of solid tumours. It also aims to establish 
whether particular chemotherapy-related cognitive deficits are associated with specific aspects of 
HRQoL. As far as the authors are aware this is the first review of its type. 
Methods 
Inclusion and exclusion criteria 
The search was limited to papers published in English post 1980, as this period coincides with a 
prevalence of reporting and systematic investigation of post-chemotherapy cognitive impairment 
[20]. 
Articles were restricted to those that had recruited patients’ aged 18+ with a solid tumour such as 
breast, ovarian, CRC, prostate and lung treated with chemotherapy. Studies of patients with brain 
tumours and central nervous system tumours were excluded because of the inherent effects of the 
tumour on cognition, as well as the fact that the treatments often involve brain irradiation and 
surgical interventions which are known to cause additional direct effects on brain tissue secondary 
to the lesions [36,37], and consequent changes in neuropsychological functioning [38].  
Included studies were required to be full papers that assessed both cognition and HRQoL using 
standardised measures. In addition, to be included, studies needed to examine (by quantitative 
measurement) and/or report on the relationship between such objectively measured cognitive 
deficits (global cognitive deficits and/or domain specific ones) and (global or domain specific) 
measures of HRQoL. Reviews, commentaries, case reports, dissertations and conference 
abstracts were all excluded. 
 
Search strategy 
An electronic search was performed using Ovid MEDLINE, EMBASE, PsycINFO, PsycARTICLES, 
CINAHL, PubMed and Web of Science on 6 June 2016, using a combination of search terms that 
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included all known terms for cancer such as, neoplasms and oncology, treatment terms including 
chemotherapy and “systemic treatment”; HRQoL terms and terms referring to cognition and 
cognitive impairment (please see detailed search strategy in Supplementary File 1). The first 
author (MRD) agreed the search terms with a specialist librarian and the third author (CH). A 
combination of both text words and indexed terms (such as MeSH) were applied in each 
database. Search terms were modified as necessary for each electronic database. The reference 
lists of all included articles were also searched for additional studies. 
Study selection 
Once the duplicates had been removed, retrieved articles were screened by title and, if eligibility 
was unclear from the title alone, the abstracts were screened (by MRD and 10% by CH). All 
articles potentially satisfying the inclusion criteria were retrieved in full and screened for eligibility 
(again by MRD and 10% by the second author (LR)).  
Quality assessment 
As there is currently no agreed “gold standard” appraisal tool for observational studies, a quality-
scoring tool was developed based on methodological quality assessment checklists from the NICE 
“Methods for the development of NICE public health guidance” (Appendix 1) [39, 40]. Valid criteria 
(items) were selected from the NICE checklists and adapted for the purposes of this review in 
order to ensure that the 5 recommended aspects of internal validity (i.e. a clearly focused 
question, selection of subjects, assessments, confounders and statistical analysis), together with 
an overall assessment of the study were addressed in the evaluation of quality. A total of 16 items 
were included which covered all aspects considered necessary to evaluate the quality of the 
evidence in relation to the research question. [See Supplementary File 3.] Authors were emailed to 
obtain any missing data or details to ensure the study quality could be evaluated.  
The overall assessment for each paper was calculated by considering all 16 items and then 
attributing scores between 0-4 to the overall assessment of the study; considering the extent to 
which each study was internally and externally valid. The higher the score the less bias in the 
study and the more external validity. Two studies had the highest overall rating score of 4 [39 & 
42], five studies scored 3 [10/14, 20, 43, 44/45,46]; nine scored 2 [11, 19, 29, 47, 48, 49, 50,51, 
52] and one was rated 0 [53].  MRD assessed each included study and LR independently coded 
the quality of the studies to check the reliability of the quality assessment. Agreement between the 
coders was substantial (kappa = 0.675) and MRD’s final score was used. Although the 
methodological quality of each study was evaluated and discussed, studies were not eliminated 
from this review because of poor quality.  
Results 
Literature search results 
Database searches identified 2796 citations, and 36 additional citations were retrieved from 
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reference lists. Screening of titles and abstracts identified 365 potentially eligible articles (Figure 
1).  
The full texts of 59 papers were reviewed, 20 satisfied the inclusion criteria. An examination of the 
reference lists did not identify any additional papers that met the inclusion criteria. Several papers 
were linked and consequently treated as a single study ([10 and 14], [44 and 45] and [54 and 42]). 
This resulted in the final inclusion of 17 studies, whose main characteristics are presented in the 
Supplementary File 2. 
Defining Cognitive Impairment 
The calculation and operational definition of what constitutes cognitive impairment varied widely 
across studies (See Table 1). More than half of the studies (n = 10) converted raw scores into 
standardised z-scores (mean = 0, SD = 1) using published normative data adjusted for age, 
education, and gender. However, the number of tests and the extent to which these z-scores had 
to deviate to constitute cognitive impairment varied across the studies. Definitions of cognitive 
impairment included z-scores of ≤ −1.4, -1.5 and -2 standard deviations (SD) below the mean on 
between 1-4 tests. (See Supplementary File 2 for the full list of operational definitions used.) The 
extent of impairment has been shown to be dependent on the method of analysis [55]. As a 
consequence of the differences across the studies it is not possible to provide a simple estimate of 
the prevalence of cognitive impairment in patients treated with adjuvant chemotherapy. Ignoring 
these methodological differences, all but two studies [50, 53] reported statistically significant 
cognitive dysfunction in some patients undergoing adjuvant chemotherapy treatment.  
Affected Cognitive Domains and Assessment of Objective Cognitive Impairment 
The cognitive domains most affected varied widely across studies. Four studies [11, 41, 42& 44] 
reported verbal memory as being most affected whereas [42, 43, 46 & 47] and [29, 48] found that 
the most common domains showing decline were processing speed and executive function. Two 
studies [50 & 53] reported that objective cognitive performance remained constant throughout 
treatment.  
As shown in Table 1 multiple tools were used and many different cognitive domains (as reported 
by the authors of the articles) were measured. Not only did the studies assess different areas of 
cognition but they also used different tests to assess the same domains. Overall there were more 
than 54 different measures used across 17 studies to tap a variety of cognitive domains. The 
majority of studies (n = 15) used a battery of neuropsychological tests assessing a range of 
domains. It is worth noting that the different psychometric qualities of each of the measures may 
have influenced the conclusions drawn regarding the cognitive domains most affected by 
chemotherapy treatment. For example, no impairment was reported by [53] who used the Mini-
Mental State Examination (MMSE), which has been criticised for not being sensitive enough to 
detect subtle cognitive changes [56, 57].  
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This problem of diversity of assessments used has been recognised as an issue that needs 
consideration in future research by the International Cognition and Cancer Task Force (ICCTF) 
[58]. In an attempt to bring some homogeneity to all studies, the ICCTF recommended that in 
future trials 3 core neuropsychological assessments (the Hopkins Verbal Learning Test-Revised 
(HVLT-R), Trail Making Test (TMT), and the Controlled Oral Word Association (COWA) of the 
Multilingual Aphasia Examination)[59-63] be used to measure learning and memory, processing 
speed and executive function, supplemented with additional tests of working memory capacity, 
based on the researchers own preferences [58]. This was justified by the assertion that research 
has shown that the domains assessed by these tests are most affected by chemotherapy 
treatment [58]. However no study undertaken post ICCTF’s recommendations used the entire core 
battery to assess neuropsychological impairment although 3 earlier studies did [48, 49, 50].    
Assessing HRQoL 
HRQoL was assessed at the same time points as cognition in all included studies. As with the 
neuropsychological assessments some studies reported having analysed only global HRQoL 
scores [14, 19, 48, 53] whereas others extended the analysis to the subscales of the HRQoL 
measure [11, 20, 41, 43, 46, 47, 52].  
Five studies assessed HRQoL using the European Organization for Research and Treatment of 
Cancer Quality of Life questionnaire (EORTC–QLQ C30); the remaining studies used one or more 
of the questionnaires from the Functional Assessment of Cancer Treatment (FACT) battery. Both 
the EORTC–QLQ C30 and FACT-G are generic core HRQoL questionnaires supplemented by 
disease specific modules (e.g. the FACT-B for breast cancer). Both have subscales measuring 
key aspects of HRQoL (physical, emotional, social and functional), however the EORTC–QLQ 
C30 also provides brief scales for cognitive functioning, financial impact and a range of symptoms 
which are either not assessed by the FACT-G or are embedded within its wellbeing scale [64, 65]. 
The EORTC-QLQ C30 also provides 5 “functioning” scales and 10 symptom scores compared to 
FACT-G, which gives 5 summary scales (4 “well-being” and 1 overall scale) [65]. There are also 
differences between the 2 batteries’ social domains. EORTC QLQ–C30’s social functioning scale 
assesses the impact on social activities and family life whereas the FACT–G social well-being 
subscale focuses on social support and relationships [66]. As both scales are widely used but 
measure markedly different aspects of HRQoL, a direct comparison of results between studies 
using different scales is not possible [67].  
The Relationship Between Objective Cognitive Dysfunction and HRQoL   
Table 1 shows that 3 [51, 41, 43] of the 17 studies found a significant relationship between 
objectively assessed cognitive impairment and HRQoL. Two studies [51, 43] demonstrated that 
the greater the cognitive impairment related to chemotherapy the worse the patient’s self-reported 
HRQoL as measured by the EORTC-QLQ C30 or the FACT battery. The third study [41] 
suggested patients with lower functional well-being at baseline are at greater risk of cognitive 
impairment after chemotherapy. All 3 studies examined the inter-relationships between various 
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domains of HRQoL and specific impaired cognitive domains, with 2 of them [51 and 43] 
specifically examining the presence of post-treatment cognitive deficits whereas the third study 
[41] examined deficits over the course of treatment. 
The significant relationships were different in all 3 studies. For example, one study [51] found that 
objective measures of verbal memory were associated with poorer HRQoL (as measured by 
EORTC-QLQ C30) 5 years after treatment. Another [43] reported that poorer functional well-being 
(as measured by FACT-B) was significantly associated with verbal fluency at 12 months post-
chemotherapy (although only a small proportion of participants’ demonstrated objective cognitive 
decline). The third study [41] found that lower functional well-being at baseline (pre-chemotherapy 
treatment) significantly contributed to changes over the course of treatment in the cognitive 
domains of attention and executive function rather than declines in well-being affecting cognitive 
functioning shortly after finishing chemotherapy treatment.  
The remaining studies included in this review found no correlation between overall objective 
cognitive impairment and overall HRQoL or between any of the specific domains. One study [49] 
did observe that those with the most dysfunction who improved also showed an improvement in 
overall global HRQoL. Unfortunately no statistics or specific details were provided to back up this 
assertion.  
 
Methodological Quality 
It is noteworthy that 11 studies (65%) [10/14, 29, 41, 43, 44/45, 46, 47, 48, 49, 50 & 51] were 
exclusively on breast cancer, one was with a mixed solid tumour patient group [53], 2 examined 
CRC patients [11,42], another examined patients with ovarian cancer [19] and one examined lung 
cancer patients [52]. In addition to variations in study samples, there were many differences in the 
designs and measurement points across the studies (Figure 2) which make it difficult to draw 
overall conclusions from this body of work. Twelve studies [11, 14, 19, 29, 41, 42, 43, 45, 48, 49, 
52, 53] were longitudinal, with 10 (59%) having pre-chemotherapy baseline assessments. Four of 
the longitudinal studies with pre-treatment assessments [11, 19, 42, & 48] also examined cognition 
during chemotherapy treatment. Follow-up periods varied across the studies, ranging from end-of- 
treatment [53] to 2 years post-treatment [14]. One longitudinal study assessed cognition at 3 time-
points post-chemotherapy [43].  
 
Eight studies [14, 20, 41, 42, 45, 46, 50, 51] included more than one group. Three compared 
groups with different types of treatment or stages of disease (e.g. standard dose chemotherapy 
compared to high dose [51, 20, 41]).  Two studies [42 & 51] compared the different chemotherapy 
groups to an early stage cancer group who did not need chemotherapy; and 3 studies compared 
chemotherapy patients to healthy controls [45, 10/14, 42]. The healthy control groups studies were 
peer-nominated (i.e. friends and family of the patient participants). The healthy controls were a 
useful comparator as they were matched for age and socioeconomic status. However, it should be 
noted that the cognitive evaluation in the patient group may be confounded by the stress 
associated with a cancer diagnosis and consequent surgery [12]. This raises the question as to 
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whether a healthy control group is the ideal comparison group in this context. Two studies used 
two comparison groups [55, 42] a non-chemotherapy group (post-surgery and had commenced 
endocrine therapy) as well as healthy controls (friends and family of the patient participants) [42, 
58]. 
 
Eight studies recruited participants from a single hospital site [11, 20, 29, 46, 48, 49, 50 & 53] and 
the remaining 9 studies recruited from 2 or more sites making these results potentially more 
generalisable. Of the 8 single-site studies, 4 had sample sizes of fewer than 50 participants 
despite long recruitment periods. For example, one study recruited only 28 breast cancer 
participants over 2 years [49] and [50] was a pilot study with only 17 participants. In contrast, 2 
single site studies [11 & 53] recruited over 80 participants each but both had high attrition rates 
(33% & 21%) and neither was sufficiently powered. Overall 59% of studies [11, 20, 41, 43, 47, 48, 
51, 52, 50, 53] were underpowered and/or did not provide sample size justifications. 
 
Of the studies with the most robust methodological designs [14, 20, 41, 48, 45, 19, 42], 3 were 
longitudinal and had the largest sample sizes [41, 45, 14, 19, 42] a total of 159, 177, 206, 231 and 
434 participants respectively, with one or more comparison group as outlined above.  
 
Six studies were graded as having high internal validity (i.e. unbiased) [14, 41, 42, 43, 45 & 46]; 10 
as moderate [11, 19, 20, 29, 45, 47, 48, 49, 50, & 52] and one as poor [53].  Only 3 studies were 
graded as having high external validity [20, 41, & 42], 13 as moderate and one as having poor 
external validity [53]. 
Methodological shortcomings mainly concerned 3 studies [ 48, 49, 44/45] which were exploratory 
in nature with no focussed objective, 7 studies [11,19, 42, 43, 47, 49 & 50] which failed to report 
the acceptance rate of invited participants and 8 of the longitudinal studies [11,14,19, 42,43,48,52 
& 53] (60%) which had attrition rates exceeding 20%.  
Of the 3 studies that reported a relationship between objectively measured cognitive deficits and 
HRQoL one was cross-sectional [51] and 2 longitudinal in design [41, 43]. The focus of each was 
slightly different. For example, one study [51] examined neuropsychological impairment and 
HRQoL in high-risk breast cancer survivors 5 years after treatment. A second [43] examined the 
relationship one month after treatment and followed up the participants for another 12 months and 
the third study [41] investigated whether HRQoL significantly contributed to cognitive dysfunction 
reported after chemotherapy, examining cognition pre-treatment and 4 weeks post-treatment.  
In interpreting the quality of the studies that found a significant relationship between cognitive 
decline and HRQoL, the cross-sectional study [51] had a low quality rating (1), and therefore the 
results should be treated with caution. Both longitudinal studies [41,43] received a higher overall 
quality score (3 and 4 respectively) suggesting that the results are more robust. All 3 studies 
examined cognitive impairment post-treatment, although one [41] also assessed pre-treatment 
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cognition. The results of these studies are difficult to compare because of their different aims, 
designs, participants and measures.  
 
Conclusion 
 
This review set out to examine studies that explored the possibility of a direct relationship between 
the adverse cognitive effects of chemotherapy treatment in patients with solid tumors and HRQoL. 
A critical examination of identified studies indicates that objective cognitive impairment is subtle 
and only occurs in a subset of patients. Processing speed, executive function and verbal fluency 
were the most commonly reported affected domains in the papers reviewed here. Although the 
review established that there is limited evidence to indicate that such cognitive impairment puts 
patients treated with adjuvant chemotherapy at greater risk of poorer HRQoL there is a suggestion 
that some HRQoL domains are affected.  
There are a number of possible explanations for the limited number of studies reporting a 
significant relationship between impaired cognition and HRQoL.  One explanation for some 
findings which failed to find any such relationship may be that the studies which used a global 
cognitive impairment score and/or a global HRQoL score masked the more subtle relationships or 
associations which possibly existed between specific cognitive domains and different aspects of 
HRQoL. For example, 2 studies [14 & 20] that combined test scores to produce an overall 
measure of cognitive impairment failed to find any correlation with HRQoL. In contrast one study 
[43] did find evidence of women who experienced greater executive function deficits reporting 
more difficulties in functioning in social roles. This however cannot account for all the failures to 
find a relationship between impaired cognition and HRQoL as one study [52] that did examine 
possible relationships between each neuropsychological test result and all HRQoL variables also 
did not find any statistically significant correlations at the three assessed time points. 
 
A further caution is required when considering the number of studies that failed to find any such 
relationship. Most of the studies did not set out to explore this relationship; rather it typically 
featured as an exploratory post-hoc analysis.  
Future research is needed to examine the relationship more thoroughly as more people who are 
diagnosed with cancer are surviving longer. If chemotherapy-related cognitive impairment is 
associated with feelings of low competence, survivors may encounter problems returning to work 
[6] and/or withdrawal from social life [30] both important consequences that need to be addressed.  
An additional complication when attempting to gain clarity in this research revolves around 
different assessments used and the variability in the definition of cognitive impairment. Going 
forward, consistent use of the recommended tests and definitions should provide a clearer picture 
of the type and extent of deficits suffered by different cancer patients undergoing chemotherapy 
treatment [58]. 
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A similar issue relates to the definition and questionnaires used to assess HRQoL. There are 
many instruments available for assessing HRQoL, from generic (measuring multiple concepts 
relevant to a wide range of patients) to specific (a disease, population or health dimension) [68]. 
All studies in this review used one of two instruments, the EORTC–QLQ C30 or the FACT battery. 
The findings indicated the difficulty in drawing meaningful comparisons between the results 
obtained by these two measures. There were insufficient data to examine which affected cognitive 
domains were related to which particular aspects of HRQoL. Even amongst the 3 studies that did 
find specific relationships it was not feasible to draw any meaningful comparisons between them 
as they used different HRQoL measures. A further complication is that in the studies on women 
with breast cancer some patients often received endocrine therapy as well as chemotherapy, 
making it difficult to distinguish the particular role of chemotherapy in relation to HRQoL.   
Although almost all the studies found some type of cognitive impairment in a small subset of 
participants, such impairment often improved for some patients after treatment [14, 29, 49, 52]. It 
is common with repeated assessments of neuropsychological performance that individuals show 
some improvement even when alternate forms of the same test are used. This emphasizes the 
need for a control group so as to be able to examine and compare the practice effects when 
repeatedly using these tests over time [58].  
If the heterogeneity between future studies can be reduced, valuable information may be gained 
which could effectively inform suitable interventions for decreasing the effects of chemotherapy-
related cognitive deficits and potentially improving HRQoL [69]. This would help those susceptible 
to impairment to cope or more fully understand the implications of side effects, particularly if their 
diagnosis means that chemotherapy is an option rather than a requirement.  
Strengths and limitations of the review  
This review is not without its limitations. For example, all studies regardless of quality were 
included in the review because it is an under researched area.  Most were of moderate quality at 
best and not necessarily methodologically robust enough to answer the review question.  
Implication 
The review highlights the need for more appropriately powered studies with suitable comparison 
group(s) along with greater overlap of instruments used and consistency in concepts especially 
the definition of cognitive deficit to advance our understanding of chemotherapy, cognition and 
HRQoL.  
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Table1: Summary of measures, cognitive domains as defined by the authors, objective cognitive impairment (CI) and the relationship between CI and 
HRQoL  
 
Article 
& year 
 
 
CI?  
 
 
HRQoL 
Measure 
CI 
significantly 
correlated 
with 
HRQoL?  
 
Cognitive Domain Measured 
 
    Processing 
speed 
Memory Attention Learning Executive 
Function 
Self-
regulation 
& 
planning 
Spatial 
Function 
Language/ 
Verbal 
Function 
 
    Verbal Visual Working Attentio
n 
Visual motor/ 
psychomotor 
function 
Verbal     
[11]  
2014 
 EORTC 
QLQ C30 
X  Subtest of 
Barcelona 
Test – 
Imm Mem, 
Imm Mem-
Q, 
Delayed 
Mem, 
Delayed 
Mem-Q 
  TMT A* WAIS-R digit 
symbol 
 Stroop C-W, 
colour & 
word;  
TMT B* 
   
[50]  
2002 
X FACT B X TMT A* & B* 
PASAT 
Stroop Word, 
Colour, C-W 
COWAT 
TMT B* 
Category Test 
HVLT-R* 
WMS III- Faces I & II 
RBANS 
 
TMT A* 
&B* 
Category 
Test 
HVLT-R* 
Faces I & 
II 
PASAT 
RBANS 
Stroop 
Word, 
Colour,  
C-W 
COWAT 
 
TMT A* &B* 
Grooved 
Pegboard 
RBANS 
Sensory 
Perceptual 
Exam 
 TMT B* 
Category Test 
PASAT 
Stroop C-W 
  HVLT-R* 
RBANS 
COWAT 
[19]  FACT O  X CRT    CRT CRT      
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2015 
 
[49]  
2006 
 FACT B X  HVLT –R* RCFT  TMT A* WAIS-III digit 
symbol,  
TMT A & B 
 TMT B*, 
Stroop colour 
& word, 
COWAT* 
 WAIS-III 
Block 
Design, 
RCFT  
WRAT – 3 
Reading 
subtest, 
Boston 
naming test, 
COWAT* 
[53] 
2004 
X EORTC 
QLQ C30 
X 
 
 
    MMSE      MMSE 
[51] 
2007 
 EORTC 
QLQ C30 
 
 VLMT – 
Form A 
ROCFT 
 
 
WMS-R TMT A & 
B*, TAP, 
Test D2 
 
  RWT, LPS-3, 
LPS -4 
   
[47] 
2009 
 FACT B X 
 
 WMS-III Logical Memory 
I & II, Visual 
Reproduction I & II, Rey 
AVLT Delayed Recall 
 
  WAIS-III digit 
span,  
TMT A* 
 TMT B*, 
Stroop 
  COWAT*, 
Category 
Fluency 
[43] 
2010 
 FACT B & 1 
single item 
question (‘in 
general, how 
satisfied are 
you with 
your overall 
quality of 
life’) 
 TMT A & B* WMS-III Logical Memory 
I & II, Rey AVLT 
Delayed Recall & Trials 
1-5 
    Stroop   COWAT*, 
Category 
Fluency 
[46]  
1999 
 EORTC 
QLQ C30 
X FVRT; FBCT;   
FVST 
RAVLT RCFT 
 
WMS-R 
Visual 
Reproducti
on – imm, 
delayed & 
recall 
 D2 
 
WAIS- 
digit 
symbol 
 
WAIS- 
digit span 
FFTT  
 
TMT A* 
 TMT B*, 
Stroop 
  Word fluency 
subtest from 
S.A.N test 
[44/45]   
2006 
 FACT B & 
ES (patients 
only)  
X Letter 
cancellation 
task 
WMS 
logical 
memory, 
imm & 
delayed, 
RCFT 
 
 
WMS  III - 
spatial span, 
letter/ 
number 
sequencing 
   Stroop    
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RAVLT 
recall 1-7 
& digit span 
[10/14] 
2005 
 FACT-G 
Version 4 
FACT ES 
X 
 
 
HSCS    HSCS, 
CPT 
HSCS, TMT A 
&B* 
  HSCS HSCS HSCS 
[20]  
1998 
 
 EORTC 
QLQ C30 
X 
 
FVRT; FBCT;   
FVST 
 
REY15 
words 
 
Complex 
figure 
 D2 test 
WAIS- 
digit 
symbol 
WAIS- 
digit span 
TMT A* 
FFTT 
 Stroop 
TMT B* 
 RCFT 
(copy) 
Word Fluency 
subtest from 
the DAST 
[54/42] 
2015 
 FACT G X WAIS III Digit 
Symbol 
TMT A & B* 
HVLT-R* 
CANTAB - 
VRM 
 
BVMT-R CANTAB - 
SWM 
CANTAB - 
RVP 
CANTAB – MOT 
& RVP & RTI 
CANTAB - 
VRM 
    
[41] 
2009 
 
 FACT G  SDMT AVLT WMS-III 
Visual 
Reproducti
on – imm, 
delayed & 
recognitio
n 
WAIS-III 
Backward 
digit span 
TEA 
Visual 
Elevator & 
Telephone 
search 
Purdue 
Pegboard 
 WAIS-III 
Matrix 
Reasoning 
Stroop, 
DKEFS Card 
sorting, 
COWAT* 
   
[29] 
2004 
 FACT B X 
 
WAIS-R Digit 
Symbol, TMT 
A* 
VSRT delayed recall, NVSRT delayed 
recall 
WAIS-R 
Digit Span 
& 
Arithmetic 
Grooved 
Pegboard 
VSRT Long 
term 
storage, 
NVSRT 
Long term 
storage 
TMT B*, 
Booklet 
Category Test, 
WAIS-R 
Similarities 
 WAIS-R 
Block 
Design 
 
[48] 
2010 
 FACT B X 
 
WAIS-R Digit 
Symbol, TMT 
A* 
HVLT* WAIS-R 
Digit Span 
 HVLT* TMT B*, MAE 
COWA* 
   
[52] 
2008 
 FACT L X 
 
 
 HVLT—R*, RCFT Gordon 
CPT 
WAIS-block 
design 
 COWA* 
WCST-64  
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Key:  * = this is one of the ICCTF’s recommended core neurological assessments. 
EORTC QLQ C30: European Organization for Research and Treatment of Cancer Quality of Life questionnaire; 
FACT O: For patients with Ovarian cancer 
FACT G: Functional Assessment of Cancer Therapy – General; FACT B: For patients with Breast cancer; FACT ES: For patients with Endocrine Symptoms; FACT L: For patients with Lung cancer; 
Imm-Mem: Immediate memory; Imm-Mem-Q: Immediate memory-questions; Delayed-Mem: Delayed memory; Delayed-Mem-Q: Delayed memory-questions; 
TMT A & B: Trial Making Test Part A & Part B; WAIS-R Digit Symbol: Wechsler Adult Intelligence Scale Revised Digit Symbol; MMSE: Mini- Mental State Examination;  
CRT: Headminder Clinical Research Tool; 
WAIS-R Digit Span: Wechsler Adult Intelligence Scale Revised Digit Span; Stroop C-W: Stroop interference trial; 
HVLT-R: Hopkins Verbal Learning Test – Revised; 
RBANS: Repeatable Battery for the Assessment of Neurospcyhological Status; 
Category Test; 
PASAT: Paced Auditory Serial-Addition Task; COWAT/COWA: Controlled Oral Word Association Test 
Grooved Pegboard; 
Sensory Perceptual Exam; 
RCFT: Rey-Osterrieth Complex Figure test; WAIS-III: Wechsler Adult Intelligence Scale –III; WRAT-3: The Wide Range Achievement Test, Third Edition; 
MMSE: Mini- Mental State Examination; 
VLMT: Auditory Verbal Learning Test – German modified version;ROCFT: Rey-Osterrieth complex figure test; TAP: Test battery for attentional performance; Test D2: D2 cancellation test;RWT: Regensburg Word Fluency Test; 
LPS: achievement measure test; 
WMS-III Logical Memory: Wechsler Memory Scale – third edition Logical Memory; WMS-III Visual Reproduction: Wechsler Memory Scale – third edition Visual Reproduction; Faces I & II: Facial Recognition Tests; 
RAVLT/Rey AVLT: Rey Auditory Verbal Learning Test; FFTT: Fepsy finger-tapping task; FVRT: Fepsy visual reaction test; FBCT: Fey binary choice test; FVST: Fepsy visual searching test; 
S.A.N Test: Please see full reference in Supplementary File 4 
Letter cancellation test; 
HSCS: High Sensitivity Cognitive Screen; CPT: Continuous Performance Test; DAST: Dutch Aphasia Society Test;  
CANTAB Battery: RVP: Rapid Visual Information Processing; RTI: Reaction Time; VRM: Verbal Recognition Memory; SWM: Spatial Working Memory; MOT: Motor Screening; 
BVMT-R: Brief Visuospatial Memory Test Revised; SDMT: Symbol Digit Modalities Test; TEA: Test of Everyday Attention; 
Elevator & Telephone search; 
Perdue Pegboard; 
DKEFS: Delis-Kaplan Executive Function Scale; NVSRT: Nonverbal Selective Reminding Test; VSRT: Verbal Selective Reminding Test; Grooved Pegboard 
MAE COWA: Multilingual Aphasia Examination controlled oral word association; WCST-64: Wisonsin Card Sorting Test Conceptual Level Responses; Gordon CPT: Gordon Continuous Performance Test. 
See Supplementary File 4 for all of the measurement references 
 
